Lung SBRT: Motion Management Decision
A 71-year-old with a 2.1 cm peripheral right lower lobe NSCLC is planned for SBRT, 54 Gy in 3 fractions. On 4D-CT, the tumor shows 14 mm of craniocaudal motion and 4 mm of lateral motion. The patient has COPD with an FEV1 of 48% predicted and cannot tolerate a long breath-hold; he can manage about 8 seconds. The department has abdominal compression, gating, and a tracking-capable linac. The planning target volume with a free-breathing ITV approach would be large, and the physicist notes the lung V20 would rise from 12% to 18%. The patient is anxious and asks whether the treatment will 'burn' his good lung.
1. Compare the motion-management options for this patient and recommend one, with justification.
Read the worked answer
Options: (1) Free-breathing ITV with a margin - simple, but the 14 mm motion forces a large ITV and raises V20 to 18%, increasing pneumonitis risk in a patient with poor reserve. (2) Abdominal compression - reduces diaphragmatic excursion, often cuts motion to under 5 mm, is quick, and is well tolerated; it is a strong first choice here because the patient cannot breath-hold. (3) Respiratory gating - requires a stable, reproducible breathing trace; with 8-second capability the patient may not sustain a reliable gate, and gating adds setup time and complexity. (4) Tracking - most precise but resource-intensive and may not be needed if compression suffices. Recommendation: try abdominal compression first, re-scan 4D-CT, and if residual motion is under 5 mm, proceed with a reduced-margin plan; if not, consider gating with a short duty cycle or tracking. The decision should be documented with the physicist and oncologist, and the patient counseled that the goal is to spare functional lung.
2. How would you explain the V20 change and the risk of radiation pneumonitis to this anxious patient?
Read the worked answer
Explain in plain language: V20 is the percentage of lung receiving at least 20 Gy, a threshold linked to pneumonitis risk. Going from 12% to 18% raises the estimated risk of clinically significant pneumonitis from roughly 5–10% to perhaps 15–20%, though the exact risk depends on his baseline function. Emphasize that his COPD means we want to protect as much healthy lung as possible, which is why we are choosing a motion technique that shrinks the treated volume. Reassure him that SBRT is highly effective for his stage of cancer, that we will monitor for cough, fever, or breathlessness, and that most patients do not develop severe pneumonitis. Avoid promising zero risk; honesty builds trust. Document the discussion and his questions.